J&J Quickly Advances BCMA-Targeting CAR-T As JNJ-4528 Shows 100% Response

Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.

3d illustration of T cells or cancer cells
Myeloma patients have responded well to T-cells engineered to target BCMA. • Source: Shutterstock

Development of Janssen Pharmaceutical Cos.’ JNJ-4528 is several months behind the most advanced B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) therapy, but the Johnson & Johnson subsidiary is running at full speed to generate pivotal trial results and move into earlier lines of multiple myeloma treatment based on strong Phase Ib responses.

Even so, Bristol-Myers Squibb Co. and its partner bluebird bio Inc. are working hard to maintain the likely first-to-market advantage for their BCMA-targeting CAR-T therapy idecabtagene vicleucel (ide-cel;...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By 

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By 

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.

Progress In The Effort To Improve Outcomes In SCLC

 

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

More from Therapy Areas

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By 

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By 

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.